Influenza vaccine production is the subject of an agreement between Neugenesis and the international nonprofit PATH. Under the agreement, Neugenesis will conduct proof-of-concept work to demonstrate the utility of its NeuBIOS protein production platform for making seasonal and pandemic influenza vaccine, according to an announcement.
The Neugenesis platform provides high-level expression of recombinant, multivalent, influenza virus antigens from the transformed filamentous fungus, Neurospora crassa. The company says the platform is "scalable, inexpensive, and can be upgraded with genes for new influenza variant antigens to produce new vaccines in weeks, rather than months." Under the PATH agreement, the NeuBios platform will be used to make non-infectious, non-replicating virus-like particles.
The platform will help PATH in its efforts to develop pandemic-response influenza vaccines that will be safe, effective, and affordable for distribution by public health systems in low-income countries.
- here's the announcement